Table 1.
Patients' characteristics.
| Number of patients | 62 |
|---|---|
| Age, median (range) in years | 64 (27–80) |
| Gender, n (%) | |
| Male | 36 (58%) |
| Female | 26 (42%) |
| Prior therapies, n (%) | |
| Surgery | 49 (79%) |
| Somatostatin analog | 44 (71%) |
| Systemic therapies | 6 (10%) |
| PRRT | 9 (15%) |
| Local therapies (SIRT, RFA, and TACE) | 4 (6%) |
| Primary tumor site, n (%) and grading, n (%) | |
| Gastroenteropancreatic | 53 (85%) |
| G1 | 20 (38%) |
| G2 | 31 (58%) |
| G3 | 2 (4%) |
| Bronchopulmonary | 6 (10%) |
| G1 | 0 (0%) |
| G2 | 6 (100%) |
| G3 | 0 (0%) |
| Cancer of unknown primary | 3 (5%) |
| G1 | 1 (33%) |
| G2 | 2 (67%) |
| G3 | 0 (0%) |
| Cycles of PRRT, n (%) | |
| 2 | 7 (11%) |
| 3 | 10 (16%) |
| 4 | 31 (50%) |
| >4 | 14 (22%) |
SIRT, selective internal radiation therapy; RFA, radiofrequency ablation; TACE, trans-arterial chemoembolization; G, grading.